EGFR and neoplasm: Although the results of the Phase III EXCLAIM-2 study fell short of expectations, leading to the withdrawal of Mobocertinib, other drugs, such as the domestically developed third-generation EGFR TKI Furmonertinib (80) and DZD9008, have shown outstanding anti-tumor activity in EGFR ex20ins patients, particularly those with brain metastases (69, 82, 84).